{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T06:39:15Z","timestamp":1794465555044,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SOS\/VOD is a life-threatening complication of hematopoietic stem cell transplantation, especially in children, with incidences reaching up to 15\u201320%. Despite efforts, SOS\/VOD remains unpredictable with significant morbidity and mortality. High-risk criteria are clearly defined, and the pediatric EBMT diagnostic criteria have improved sensitivity, reducing treatment delays and enhancing outcomes. A meta-analysis combining retrospective and prospective studies found a risk ratio of 0.30 for SOS\/VOD with defibrotide (DF) prophylaxis. Additionally, two prospective trials were conducted: the pediatric prevention trial (NCT00272948) and the Harmony Trial (NCT02851407), involving adults and children, with primary outcomes of incidence and SOS\/VOD-free survival, respectively. The trials produced conflicting results regarding the effectiveness of prophylactic DF. Despite significant limitations of the Harmony trial, a direct healthcare professional communication (DHPC) from the European Medicines Agency (EMA) advised against prophylactic DF. This recommendation has serious consequences for children, especially infants, who are among the most vulnerable groups receiving HSCT. Therefore, a panel of experts issued guidelines for children at high risk for SOS\/VOD, in which DF prophylaxis is considered justified. These guidelines include a weighted scoring system based on all relevant high-risk criteria to predict SOS\/VOD, supporting decisions regarding the use of prophylactic DF in children.<\/jats:p>","DOI":"10.1038\/s41409-025-02793-x","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:28:12Z","timestamp":1768339692000},"page":"417-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Defibrotide for prophylaxis of sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1070-8486","authenticated-orcid":false,"given":"Selim","family":"Corbacioglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-0322","authenticated-orcid":false,"given":"Rajinder","family":"Bajwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-6021","authenticated-orcid":false,"given":"Ali B\u00fclent","family":"Antmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-0610","authenticated-orcid":false,"given":"Adriana","family":"Balduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-9547","authenticated-orcid":false,"given":"Simone","family":"Cesaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-801X","authenticated-orcid":false,"given":"Antonio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Dignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1447-7286","authenticated-orcid":false,"given":"Katharina","family":"Kleinschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-9674","authenticated-orcid":false,"given":"Kris M.","family":"Mahadeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-0333","authenticated-orcid":false,"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Sedlacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-4482","authenticated-orcid":false,"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6352-6956","authenticated-orcid":false,"given":"Jerry","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1069-9404","authenticated-orcid":false,"given":"Zofia","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6846-6048","authenticated-orcid":false,"given":"Elif","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-6202","authenticated-orcid":false,"given":"Marta","family":"Verna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4514-8637","authenticated-orcid":false,"given":"Akif","family":"Yesilipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8818-1744","authenticated-orcid":false,"given":"Marco","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1174-5799","authenticated-orcid":false,"given":"Krzysztof","family":"Kalwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the EBMT Paediatric Diseases Working Party","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"2793_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1094","volume":"6","author":"K Kleinschmidt","year":"2025","unstructured":"Kleinschmidt K, Troeger A, Foll J, Hanafee-Alali T, Jakob M, Kramer S, et al. Defibrotide for the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome in paediatric patients who did not receive haematopoietic stem cell transplantation: case reports of patients from a German academic hospital. EJHaem. 2025;6:e1094. https:\/\/doi.org\/10.1002\/jha2.1094.","journal-title":"EJHaem"},{"key":"2793_CR2","unstructured":"Esposto MP, Milani E, Tridello G, Caddeo G, Bonetti E, Pezzella V et al. Hepatic veno-occlusive disease (VOD) as a complication of hematopoietic stem cell transplantation (HSCT) or after chemotherapy alone in the pediatric population: a single-center experience. In: Proceedings of the EHA 2025 Congress. Milan, Italy: European Hematology Association; 2025."},{"key":"2793_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jcyt.2023.10.008","volume":"26","author":"S Escribano-Serrat","year":"2024","unstructured":"Escribano-Serrat S, Rodr\u00edguez-Lobato LG, Charry P, Mart\u00ednez-Cibrian N, Su\u00e1rez-Lled\u00f3 M, Rivero A, et al. Endothelial activation and stress index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis. Cytotherapy. 2024;26:73\u201380. https:\/\/doi.org\/10.1016\/j.jcyt.2023.10.008.","journal-title":"Cytotherapy"},{"key":"2793_CR4","doi-asserted-by":"publisher","unstructured":"Balaguer-Rosell\u00f3 A, Montoro J, Villalba M, Lizama P, Torres L, Chor\u00e3o P et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther 2025 https:\/\/doi.org\/10.1016\/j.jtct.2025.05.018.","DOI":"10.1016\/j.jtct.2025.05.018"},{"key":"2793_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li AM, et al. Exagamglogene autotemcel for transfusion-dependent beta-thalassemia. N Engl J Med. 2024;390:1663\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2309673.","journal-title":"N Engl J Med"},{"key":"2793_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, et al. Betibeglogene autotemcel gene therapy for non-beta(0)\/beta(0) genotype beta-thalassemia. N Engl J Med. 2022;386:415\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2113206.","journal-title":"N Engl J Med"},{"key":"2793_CR7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2018;53:138\u201345. https:\/\/doi.org\/10.1038\/bmt.2017.161.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(11)61938-7.","journal-title":"Lancet"},{"key":"2793_CR9","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/meg.0000000000001802","volume":"33","author":"Y Xia","year":"2021","unstructured":"Xia Y, Qin H, Yang J. Hepatic veno-occlusive disease development in the hematopoietic stem cell transplantation patients: incidence and associated risk factors, a meta-analysis. Eur J Gastroenterol Hepatol. 2021;33:872\u201384. https:\/\/doi.org\/10.1097\/meg.0000000000001802.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2793_CR10","doi-asserted-by":"publisher","unstructured":"Vythoulkas D, Tsirigotis P, Griniezaki M, Konstantellos I, Lazana I. Endothelial dysfunction syndromes after allogeneic stem cell transplantation. Cancers 2023;15 https:\/\/doi.org\/10.3390\/cancers15030680.","DOI":"10.3390\/cancers15030680"},{"key":"2793_CR11","doi-asserted-by":"publisher","unstructured":"Mohty M, Malard F, Alaskar AS, Aljurf M, Arat M, Bader P et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl 2023 https:\/\/doi.org\/10.1038\/s41409-023-01992-8.","DOI":"10.1038\/s41409-023-01992-8"},{"key":"2793_CR12","doi-asserted-by":"publisher","unstructured":"Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial. Biol Blood Marrow Transpl 2010 https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.009.","DOI":"10.1016\/j.bbmt.2010.02.009"},{"key":"2793_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hep.1840040121","volume":"4","author":"GB McDonald","year":"1984","unstructured":"McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116\u201322.","journal-title":"Hepatology"},{"key":"2793_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778\u201383.","journal-title":"Transplantation"},{"key":"2793_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl. 2010;16:157\u201368. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.024.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl. 2016;51:403\u20139. https:\/\/doi.org\/10.1038\/bmt.2015.283.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR17","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.bbmt.2020.03.011","volume":"26","author":"S Corbacioglu","year":"2020","unstructured":"Corbacioglu S, Kernan NA, Pagliuca A, Ryan RJ, Tappe W, Richardson PG. Incidence of anicteric veno-occlusive disease\/sinusoidal obstruction syndrome and outcomes with defibrotide following hematopoietic cell transplantation in adult and pediatric patients. Biol Blood Marrow Transpl. 2020;26:1342\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.011.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14727","volume":"178","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112\u20138. https:\/\/doi.org\/10.1111\/bjh.14727.","journal-title":"Br J Haematol"},{"key":"2793_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"2793_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41409-020-00998-w","volume":"56","author":"D Ragoonanan","year":"2021","unstructured":"Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, et al. Improved detection of sinusoidal obstructive syndrome using pediatric-AYA diagnostic criteria and severity grading. Bone Marrow Transpl. 2021;56:175\u201384. https:\/\/doi.org\/10.1038\/s41409-020-00998-w.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100728","volume":"33","author":"D Ragoonanan","year":"2024","unstructured":"Ragoonanan D, Abdel-Azim H, Sharma A, Bhar S, McArthur J, Madden R, et al. Retrospective analysis of veno-occlusive disease\/sinusoidal obstruction syndrome in paediatric patients undergoing hematopoietic cell transplantation\u2014a multicentre study. Lancet Reg Health Am. 2024;33:100728. https:\/\/doi.org\/10.1016\/j.lana.2024.100728.","journal-title":"Lancet Reg Health Am"},{"key":"2793_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0918-1","author":"Z Szmit","year":"2020","unstructured":"Szmit Z, Gorczynska E, Kr\u00f3l A, Ussowicz M, Mielcarek-Siedziuk M, Olejnik I, et al. Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? Prospective evaluation of pediatric EBMT criteria for VOD. Bone Marrow Transpl. 2020. https:\/\/doi.org\/10.1038\/s41409-020-0918-1.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR23","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.bbmt.2019.11.012","volume":"26","author":"MM Embaby","year":"2020","unstructured":"Embaby MM, Rangarajan HG, Abu-Arja R, Auletta JJ, Stanek J, Pai V, et al. Refractory thrombocytopenia is a valid early diagnostic criteria for hepatic veno-occlusive disease in children. Biol Blood Marrow Transpl. 2020;26:546\u201352. https:\/\/doi.org\/10.1016\/j.bbmt.2019.11.012.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR24","doi-asserted-by":"publisher","unstructured":"Fussiova M, Svec P, Horakova J, Sedlacek P, Rohon P, Celec P et al. The importance of New EBMT Criteria on the diagnosis of veno-occlusive liver disease in children. J Clin Med 2023;12 https:\/\/doi.org\/10.3390\/jcm12030826.","DOI":"10.3390\/jcm12030826"},{"key":"2793_CR25","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","volume":"337","author":"Trial to Reduce Alloimmunization to Platelets Study G","year":"1997","unstructured":"Trial to Reduce Alloimmunization to Platelets Study G. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861\u20139 https:\/\/doi.org\/10.1056\/NEJM199712253372601.","journal-title":"N Engl J Med"},{"key":"2793_CR26","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin Z, Warren DL, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337\u201343.","journal-title":"Blood"},{"key":"2793_CR27","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737\u201344.","journal-title":"Blood"},{"key":"2793_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","volume":"33","author":"S Corbacioglu","year":"2004","unstructured":"Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transpl. 2004;33:189\u201395. https:\/\/doi.org\/10.1038\/sj.bmt.1704329.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","volume":"38","author":"S Corbacioglu","year":"2006","unstructured":"Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transpl. 2006;38:547\u201353. https:\/\/doi.org\/10.1038\/sj.bmt.1705485.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40261-022-01140-y","volume":"42","author":"S Corbacioglu","year":"2022","unstructured":"Corbacioglu S, Topaloglu O, Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease\/sinusoidal obstruction syndrome. Clin Drug Investig. 2022;42:465\u201376. https:\/\/doi.org\/10.1007\/s40261-022-01140-y.","journal-title":"Clin Drug Investig"},{"key":"2793_CR31","first-page":"795","volume":"91","author":"U Haussmann","year":"2006","unstructured":"Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III\/defibrotide therapy. Haematologica. 2006;91:795\u2013800.","journal-title":"Haematologica"},{"key":"2793_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00011-x","author":"SA Grupp","year":"2023","unstructured":"Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, et al. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023. https:\/\/doi.org\/10.1016\/s2352-3026(23)00011-x.","journal-title":"Lancet Haematol"},{"key":"2793_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02007-2","author":"S Corbacioglu","year":"2023","unstructured":"Corbacioglu S, Grupp SA, Richardson PG, Duarte R, Pagliuca A, Ruutu T, et al. Prevention of veno-occlusive disease\/sinusoidal obstruction syndrome: a never-ending story and no easy answer. Bone Marrow Transpl. 2023. https:\/\/doi.org\/10.1038\/s41409-023-02007-2.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s41409-021-01215-y","volume":"56","author":"JH Yoon","year":"2021","unstructured":"Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Incidence and risk factors of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1. Bone Marrow Transpl. 2021;56:1603\u201313. https:\/\/doi.org\/10.1038\/s41409-021-01215-y.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR35","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","volume":"24","author":"C Strouse","year":"2018","unstructured":"Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transpl. 2018;24:2072\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.013.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31396","volume":"72","author":"MQ Rahim","year":"2025","unstructured":"Rahim MQ, Rahrig AL, Dinora D, Harrison J, Green R, Carter A, et al. The benefits of prophylactic defibrotide: are the tides turning? Pediatr Blood Cancer. 2025;72:e31396. https:\/\/doi.org\/10.1002\/pbc.31396.","journal-title":"Pediatr Blood Cancer"},{"key":"2793_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.12669\/pjms.40.3.7901","volume":"40","author":"H Nisar","year":"2024","unstructured":"Nisar H, Khan M, Khattak TA, Ghafoor T, Chaudhry QUN. Incidence, management and outcome of hepatic veno-occlusive disease \/sinusoidal obstruction syndrome after hematopoietic stem cell transplant in thalassemia major patients: a prospective study of Pakistani BMT. Pak J Med Sci. 2024;40:259\u201364. https:\/\/doi.org\/10.12669\/pjms.40.3.7901.","journal-title":"Pak J Med Sci"},{"key":"2793_CR38","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41409-021-01233-w","volume":"56","author":"X Lai","year":"2021","unstructured":"Lai X, Liu L, Zhang Z, Shi L, Yang G, Wu M, et al. Hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome. Bone Marrow Transpl. 2021;56:1635\u201341. https:\/\/doi.org\/10.1038\/s41409-021-01233-w.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR39","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1097\/MPH.0000000000001475","volume":"41","author":"D Choudhary","year":"2019","unstructured":"Choudhary D, Doval D, Sharma SK, Khandelwal V, Setia R, Handoo A. Allogenic hematopoietic cell transplantation in thalassemia major: a single-center retrospective analysis from India. J Pediatr Hematol Oncol. 2019;41:e296\u2013e301. https:\/\/doi.org\/10.1097\/MPH.0000000000001475.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2793_CR40","doi-asserted-by":"publisher","first-page":"105.e101","DOI":"10.1016\/j.jtct.2023.10.002","volume":"30","author":"K Sakashita","year":"2024","unstructured":"Sakashita K, Yoshida N, Muramatsu H, Ohtsuka Y, Watanabe K, Yabe M, et al. Allogeneic hematopoietic cell transplantation for juvenile myelomonocytic leukemia with a busulfan, fludarabine, and melphalan regimen: JPLSG JMML-11. Transplant Cell Ther. 2024;30:105.e101\u2013105.e110. https:\/\/doi.org\/10.1016\/j.jtct.2023.10.002.","journal-title":"Transplant Cell Ther"},{"key":"2793_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27010","volume":"65","author":"B Shadur","year":"2018","unstructured":"Shadur B, Zaidman I, NaserEddin A, Lokshin E, Hussein F, Oron HC, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatr Blood Cancer. 2018;65:e27010. https:\/\/doi.org\/10.1002\/pbc.27010.","journal-title":"Pediatr Blood Cancer"},{"key":"2793_CR42","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/bjc.2016.302","volume":"115","author":"NO Basta","year":"2016","unstructured":"Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, et al. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115:1048\u201357. https:\/\/doi.org\/10.1038\/bjc.2016.302.","journal-title":"Br J Cancer"},{"key":"2793_CR43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/S1470-2045(24)00202-X","volume":"25","author":"S Corbacioglu","year":"2024","unstructured":"Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, et al. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2024;25:922\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(24)00202-X.","journal-title":"Lancet Oncol"},{"key":"2793_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.bmt.1703393","volume":"29","author":"B Horn","year":"2002","unstructured":"Horn B, Reiss U, Matthay K, McMillan A, Cowan M. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transpl. 2002;29:409\u201315.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR45","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41409-018-0298-y","volume":"55","author":"T Schechter","year":"2020","unstructured":"Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M, Desai AV, et al. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. Bone Marrow Transpl. 2020;55:531\u20137. https:\/\/doi.org\/10.1038\/s41409-018-0298-y.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR46","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1542\/peds.2005-1789","volume":"117","author":"M Ouachee-Chardin","year":"2006","unstructured":"Ouachee-Chardin M, Elie C, de Saint Basile G, Le Deist F, Mahlaoui N, Picard C, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 2006;117:e743\u2013750.","journal-title":"Pediatrics"},{"key":"2793_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/bmt.2008.133","volume":"42","author":"KS Baker","year":"2008","unstructured":"Baker KS, Filipovich AH, Gross TG, Grossman WJ, Hale GA, Hayashi RJ, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transpl. 2008;42:175\u201380. https:\/\/doi.org\/10.1038\/bmt.2008.133.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR48","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1182\/bloodadvances.2020001748","volume":"4","author":"M Felber","year":"2020","unstructured":"Felber M, Steward CG, Kentouche K, Fasth A, Wynn RF, Zeilhofer U, et al. Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis. Blood Adv. 2020;4:1998\u20132010. https:\/\/doi.org\/10.1182\/bloodadvances.2020001748.","journal-title":"Blood Adv"},{"key":"2793_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28523","volume":"67","author":"K Wustrau","year":"2020","unstructured":"Wustrau K, Greil J, Sykora KW, Albert MH, Burkhardt B, Lang P, et al. Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning. Pediatr Blood Cancer. 2020;67:e28523. https:\/\/doi.org\/10.1002\/pbc.28523.","journal-title":"Pediatr Blood Cancer"},{"key":"2793_CR50","doi-asserted-by":"publisher","unstructured":"Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl 2015 https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024.","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"2793_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41409-024-02434-9","volume":"60","author":"M Larue","year":"2025","unstructured":"Larue M, Labopin M, Brissot E, Alaskar AS, Aljurf M, Arat M, et al. An international survey to better understand the current incidence, severity, and management of VOD\/SOS. Bone Marrow Transpl. 2025;60:28\u201331. https:\/\/doi.org\/10.1038\/s41409-024-02434-9.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR52","doi-asserted-by":"publisher","unstructured":"Schechter T, Perez-Albuerne E, Lin TF, Irwin MS, Essa M, Desai AV et al. Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. Bone Marrow Transplant 2018 https:\/\/doi.org\/10.1038\/s41409-018-0298-y.","DOI":"10.1038\/s41409-018-0298-y"},{"key":"2793_CR53","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","volume":"13","author":"T Schechter","year":"2007","unstructured":"Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2007;13:307\u201314. https:\/\/doi.org\/10.1016\/j.bbmt.2006.10.026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31331","volume":"71","author":"H Goto","year":"2024","unstructured":"Goto H, Oba U, Ueda T, Yamamoto S, Inoue M, Shimo Y, et al. Early defibrotide therapy and risk factors for post-transplant veno-occlusive disease\/sinusoidal obstruction syndrome in childhood. Pediatr Blood Cancer. 2024;71:e31331. https:\/\/doi.org\/10.1002\/pbc.31331.","journal-title":"Pediatr Blood Cancer"},{"key":"2793_CR55","doi-asserted-by":"publisher","first-page":"5849","DOI":"10.1182\/blood.V124.21.5849.5849","volume":"124","author":"J Naples","year":"2014","unstructured":"Naples J, Skeens M, Bajwa R. Anicteric hepatic veno-occlusive disease after hematopoietic stem cell transplantation in children. Blood. 2014;124:5849.","journal-title":"Blood"},{"key":"2793_CR56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbmt.2014.09.026","volume":"21","author":"KC Myers","year":"2015","unstructured":"Myers KC, Dandoy C, El-Bietar J, Davies SM, Jodele S. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:379\u201381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.09.026.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR57","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1097\/MPH.0000000000002938","volume":"46","author":"F Consonni","year":"2024","unstructured":"Consonni F, Ciulli A, Cuzzubbo D, Frenos S, Sanvito MC, Tondo A, et al. Refractory thrombocytopenia is the earliest diagnostic criterion for sinusoidal obstruction syndrome in children. J Pediatr Hematol Oncol. 2024;46:e501\u2013e507. https:\/\/doi.org\/10.1097\/MPH.0000000000002938.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2793_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2014.03.039","volume":"72","author":"TD Coates","year":"2014","unstructured":"Coates TD. Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radic Biol Med. 2014;72:23\u201340. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.03.039.","journal-title":"Free Radic Biol Med"},{"key":"2793_CR59","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJM198704233161703","volume":"316","author":"G Lucarelli","year":"1987","unstructured":"Lucarelli G, Galimberti M, Polchi P, Giardini C, Politi P, Baronciani D, et al. Marrow transplantation in patients with advanced thalassemia. N Engl J Med. 1987;316:1050\u20135. https:\/\/doi.org\/10.1056\/NEJM198704233161703.","journal-title":"N Engl J Med"},{"key":"2793_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM199002153220701","volume":"322","author":"G Lucarelli","year":"1990","unstructured":"Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417\u201321.","journal-title":"N Engl J Med"},{"key":"2793_CR61","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/ajh.24674","volume":"92","author":"E Angelucci","year":"2017","unstructured":"Angelucci E, Pilo F, Coates TD. Transplantation in thalassemia: revisiting the Pesaro risk factors 25 years later. Am J Hematol. 2017;92:411\u20133. https:\/\/doi.org\/10.1002\/ajh.24674.","journal-title":"Am J Hematol"},{"key":"2793_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41409-025-02570-w","volume":"60","author":"F Ravaioli","year":"2025","unstructured":"Ravaioli F, Colecchia A, Peccatori J, Pagliara D, Grassi A, Barbato F, et al. Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentre diagnostic clinical trial. Bone Marrow Transpl. 2025;60:978\u201393. https:\/\/doi.org\/10.1038\/s41409-025-02570-w.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR63","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.bbmt.2019.01.019","volume":"25","author":"A Colecchia","year":"2019","unstructured":"Colecchia A, Ravaioli F, Sessa M, Alemanni VL, Dajti E, Marasco G, et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: results from a monocentric prospective study. Biol Blood Marrow Transpl. 2019;25:995\u20131003. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.019.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR64","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/ajh.27715","volume":"100","author":"K Masuda","year":"2025","unstructured":"Masuda K, Kataoka K, Sakurai M, Najima Y, Harada N, Ukita S, et al. Classical and late-onset SOS\/VOD after allogeneic HSCT: a Japanese transplant registry analysis. Am J Hematol. 2025;100:1283\u201394. https:\/\/doi.org\/10.1002\/ajh.27715.","journal-title":"Am J Hematol"},{"key":"2793_CR65","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1182\/blood-2024-200803","volume":"144","author":"A Alahmadi","year":"2024","unstructured":"Alahmadi A, Nasiri A, Samarkandi S, Alothaimeen H, Nassar M, Alahmari A, et al. Incidence of sinusoidal obstruction syndrome\/veno-occlusive disease in patients receiving inotuzumab ozogamicin followed by total body irradiation-based conditioning for stem cell transplantation: a risk mitigation strategy. Blood. 2024;144:7306 https:\/\/doi.org\/10.1182\/blood-2024-200803.","journal-title":"Blood"},{"key":"2793_CR66","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","volume":"40","author":"DK Cheuk","year":"2007","unstructured":"Cheuk DK, Wang P, Lee TL, Chiang AK, Ha SY, Lau YL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone marrow transplantation. 2007;40:935\u201344. https:\/\/doi.org\/10.1038\/sj.bmt.1705835.","journal-title":"Bone marrow transplantation"},{"key":"2793_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbmt.2018.09.027","volume":"25","author":"M Faraci","year":"2019","unstructured":"Faraci M, Bertaina A, Luksch R, Calore E, Lanino E, Saglio F, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease after autologous or allogeneic hematopoietic stem cell transplantation in children: a retrospective study of the Italian hematology-oncology association-hematopoietic stem cell transplantation group. Biol Blood Marrow Transplant. 2019;25:313\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.027.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2793_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(16)30114-4","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016. https:\/\/doi.org\/10.1016\/s2352-3026(16)30114-4.","journal-title":"Lancet Haematol"},{"key":"2793_CR69","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12887-020-02028-6","volume":"20","author":"X Feng","year":"2020","unstructured":"Feng X, Wu Y, Zhang J, Li J, Zhu G, Fan D, et al. Busulfan systemic exposure and its relationship with efficacy and safety in hematopoietic stem cell transplantation in children: a meta-analysis. BMC Pediatr. 2020;20:176 https:\/\/doi.org\/10.1186\/s12887-020-02028-6.","journal-title":"BMC Pediatr"},{"key":"2793_CR70","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41409-018-0281-7","volume":"54","author":"M Philippe","year":"2019","unstructured":"Philippe M, Neely M, Rushing T, Bertrand Y, Bleyzac N, Goutelle S. Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. Bone Marrow Transpl. 2019;54:448\u201357. https:\/\/doi.org\/10.1038\/s41409-018-0281-7.","journal-title":"Bone Marrow Transpl"},{"key":"2793_CR71","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00432-025-06179-w","volume":"151","author":"S H\u00e4mmerle","year":"2025","unstructured":"H\u00e4mmerle S, Ernst J, Steiner R, G\u00fcng\u00f6r T, Milde T, Gruhn B. Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2025;151:132 https:\/\/doi.org\/10.1007\/s00432-025-06179-w.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2793_CR72","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbmt.2019.10.024","volume":"26","author":"C Lewis","year":"2020","unstructured":"Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, et al. Incidence, predictors, and outcomes of veno-occlusive disease\/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:529\u201339. https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.024.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2793_CR73","doi-asserted-by":"publisher","unstructured":"Lankester AC, Albert MH, Booth C, Gennery AR, Gungor T, Honig M, et al. EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity. Bone Marrow Transpl. 2021;56:2052\u201362. https:\/\/doi.org\/10.1038\/s41409-021-01378-8.","DOI":"10.1038\/s41409-021-01378-8"},{"key":"2793_CR74","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M. Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transpl. 2019;25:1271\u201380. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2793_CR75","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15:986\u201396. https:\/\/doi.org\/10.1016\/S1470-2045(14)70281-5.","journal-title":"Lancet Oncol"},{"key":"2793_CR76","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gokbuget N, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474\u201387. https:\/\/doi.org\/10.1002\/cncr.32116.","journal-title":"Cancer"},{"key":"2793_CR77","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","volume":"4","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230\u20134. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2380.","journal-title":"JAMA Oncol"},{"key":"2793_CR78","doi-asserted-by":"publisher","unstructured":"Giglio F, Xue E, Greco R, Lazzari L, Clerici DT, Lorentino F, et al. Defibrotide prophylaxis of sinusoidal obstruction syndrome in adults treated with inotuzumab ozogamicin prior to hematopoietic stem cell transplantation. Front Oncol. 2022;12:933317. https:\/\/doi.org\/10.3389\/fonc.2022.933317.","DOI":"10.3389\/fonc.2022.933317"},{"key":"2793_CR79","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3324\/haematol.2023.284310","volume":"109","author":"S Kayser","year":"2024","unstructured":"Kayser S, Sartor C, Giglio F, Bruno A, Webster J, Chiusolo P, et al. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease. Haematologica. 2024;109:1385\u201392. https:\/\/doi.org\/10.3324\/haematol.2023.284310.","journal-title":"Haematologica"},{"key":"2793_CR80","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, et al. Biologic and clinical efficacy of lentiglobin for sickle cell disease. N Engl J Med. 2022;386:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa2117175.","journal-title":"N Engl J Med"},{"key":"2793_CR81","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/bloodadvances.2023011233","volume":"8","author":"C Marcoux","year":"2024","unstructured":"Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, et al. Incidence and risk factors of early onset VOD\/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024;8:1128\u201336. https:\/\/doi.org\/10.1182\/bloodadvances.2023011233.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02793-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02793-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:21:06Z","timestamp":1775571666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02793-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02793-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}